

# CITATION REPORT

List of articles citing

## Antimalarials in the management of discoid and systemic lupus erythematosus

DOI: 10.1016/0049-0172(78)90033-1

Seminars in Arthritis and Rheumatism, 1978, 8, 33-51.

**Source:** <https://exaly.com/paper-pdf/13500260/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
161	Ophthalmologic safety of long-term hydroxychloroquine treatment. <b>1979</b> , 22, 832-6		98
160	The regulation of prostaglandin biosynthesis: negative feedback mechanisms and the selective control of formation of I and 2 series prostaglandins: relevance to inflammation and immunity. <b>1980</b> , 6, 687-709		97
159	Antimalarials. <i>Journal of the American Academy of Dermatology</i> , <b>1981</b> , 4, 650-5	4.5	91
158	Antimalarial drugs-350 years. <b>1981</b> , 10, 307-12		7
157	Systemic lupus erythematosus--some aspects of management. <b>1981</b> , 11, 545-9		3
156	The place of antimalarials in rheumatology. <b>1981</b> , 40, 323-324		3
155	Chronic Cutaneous Lupus Erythematosus. <i>Archives of Dermatology</i> , <b>1982</b> , 118, 412		120
154	Generalized Ulcerative Sarcoidosis. <i>Archives of Dermatology</i> , <b>1982</b> , 118, 931		9
153	Therapy of cutaneous lupus erythematosus. <b>1982</b> , 66, 795-805		11
152	Antimalarials in rheumatic diseases. <b>1982</b> , 12, 645-9		7
151	Antimalarials and ophthalmologic safety. <i>Journal of the American Academy of Dermatology</i> , <b>1982</b> , 6, 19-23.5		39
150	Sunscreens: topical and systemic approaches for protection of human skin against harmful effects of solar radiation. <i>Journal of the American Academy of Dermatology</i> , <b>1982</b> , 7, 285-312	4.5	140
149	Systemic lupus erythematosus: causative factors and treatment. <b>1982</b> , 23, 481-8		3
148	Cutaneous and systemic manifestations of auto-immune disorders. <b>1982</b> , 21, 365-72		2
147	Anti-malarials in dermatology. <b>1982</b> , 21, 379-95		63
146	Chloroquine in long-term treatment of rheumatoid arthritis. <b>1983</b> , 2, 393-9		9
145	Antimalarial drugs for rheumatoid arthritis. <b>1983</b> , 75, 48-58		59

144	Chapter 18. Disease Modifying Anti-Rheumatic Drugs. <b>1983</b> , 18, 171-179		4
143	Discoid lupus erythematosus involving the eyelids. <b>1984</b> , 98, 32-6		81
142	Antimalarial Psychosis Revisited. <i>Archives of Dermatology</i> , <b>1984</b> , 120, 765		19
141	Disease-modifying antirheumatic drugs. <b>1985</b> , 5, 371-90		4
140	Toxic psychosis: a complication of antimalarial therapy. <i>Journal of the American Academy of Dermatology</i> , <b>1985</b> , 12, 863-5	4-5	30
139	Drugs in exacerbation of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>1986</b> , 15, 1007-22	4-5	181
138	The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis. <b>1986</b> , 144, 32-4, 36-7		5
137	Lupus Erythematosus in Childhood. <b>1986</b> , 4, 151-160		22
136	Systemic lupus erythematosus. <b>1986</b> , 70, 337-53		17
135	Systemic lupus erythematosus in childhood and adolescence--the problem, epidemiology, incidence, susceptibility, genetics, and prognosis. <b>1986</b> , 16, 545-625		11
134	Treatment of Discoid Skin Lesions With Azathioprine. <i>Archives of Dermatology</i> , <b>1986</b> , 122, 746		9
133	Antioxidant action of antimalarials. <b>1986</b> , 45, 244-8		40
132	Chloroquine-induced neutropenia in a patient with dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , <b>1987</b> , 16, 629-30	4-5	9
131	Free spider identification. <i>Journal of the American Academy of Dermatology</i> , <b>1987</b> , 16, 630	4-5	1
130	Scarring Alopecia. <b>1987</b> , 5, 603-618		31
129	Effect of chloroquine on cellular immune responses of normal and P. knowlesi-infected rhesus monkeys. <b>1987</b> , 65 ( Pt 3), 211-6		7
128	Antimalarial drugs and pregnancy. <b>1988</b> , 85, 30-3		58
127	Altered gentamicin disposition in a child with a cavernous hemangioma. <i>Journal of the American Academy of Dermatology</i> , <b>1988</b> , 19, 965-8	4-5	2

126	Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. <i>Journal of the American Academy of Dermatology</i> , <b>1988</b> , 19, 961-5	4.5	51
125	Treatment of systemic lupus erythematosus. <b>1988</b> , 22, 283-9		2
124	Immunosuppressive (Cytotoxic) and Immunostimulant Drugs. <i>Handbook of Experimental Pharmacology</i> , <b>1989</b> , 307-327	3.2	0
123	Noninfectious causes of fever and a rash. <b>1989</b> , 28, 145-56		1
122	Treatment of discoid lupus erythematosus. <b>1989</b> , 28, 497-507		48
121	Cutaneous lupus erythematosus. <b>1989</b> , 1, 165-200		9
120	Cutaneous reactions to drugs used for rheumatologic disorders. <b>1989</b> , 73, 1275-98		11
119	Chronic cutaneous lupus erythematosus. <b>1989</b> , 73, 1055-71		15
118	Treatment of subacute cutaneous lupus erythematosus. <b>1990</b> , 29, 542-7		24
117	Photoaging/photodamage and photoprotection. <i>Journal of the American Academy of Dermatology</i> , <b>1990</b> , 22, 1-15	4.5	225
116	A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. <b>1991</b> , 324, 150-4		507
115	Antimalarial Medications in Dermatology: A Review. <b>1991</b> , 9, 377-385		19
114	Infections in HIV-infected travelers: risks and prevention. <b>1991</b> , 114, 582-92		52
113	Hydroxychloroquine in systemic lupus erythematosus. <b>1991</b> , 325, 1046		3
112	Pregnancy outcome following first trimester exposure to chloroquine. <b>1991</b> , 8, 174-8		92
111	Auranofin in the treatment of discoid lupus erythematosus. <b>1991</b> , 2, 27-29		13
110	Treatment of cutaneous lupus erythematosus. <b>1992</b> , 1, 351-6		7
109	Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. <b>1992</b> , 51, 1318-21		47

108	Sensitivity to UV light during treatment with chloroquine in rheumatoid arthritis. <b>1992</b> , 21, 245-7		4
107	Hydroxychloroquine: a guide to usage. <b>1992</b> , 3, 103-106		8
106	Antimalarial Agents and the Eye. <b>1992</b> , 10, 513-519		
105	Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiral-chiral high-performance liquid chromatography. <b>1992</b> , 573, 253-8		39
104	Enantioselective determination of hydroxychloroquine and its major metabolites in urine and the observation of a reversal in the (+)/(-)-hydroxychloroquine ratio. <b>1993</b> , 5, 65-70		17
103	Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine. <i>Seminars in Arthritis and Rheumatism</i> , <b>1993</b> , 23, 74-81	5-3	20
102	Antimalarials for children: indications, toxicities, and guidelines. <i>Journal of the American Academy of Dermatology</i> , <b>1993</b> , 28, 764-70	4-5	35
101	Systemic lupus erythematosus in Argentina: an overview. <b>1993</b> , 2, 3-7		12
100	The Efficacy of Antimalarials in Systemic Lupus Erythematosus. <b>1993</b> , 2, 3-8		9
99	Lupus therapy. <b>1994</b> , 72, 749-53		
98	A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis. <i>Drug Safety</i> , <b>1994</b> , 11, 21-36	5-1	4
97	Discoid lupus erythematosus. <b>1995</b> , 36, 3-10; quiz 11-2		18
96	Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. <b>1995</b> , 17, 622-36		124
95	Antigen processing: the gateway to the immune response. <i>Journal of the American Academy of Dermatology</i> , <b>1995</b> , 32, 640-52	4-5	34
94	Antimalarial Drugs. <b>1995</b> , 4, 219-234		5
93	Immunopathogenesis and Therapy of Systemic Lupus Erythematosus. <b>1995</b> , 4, 471-493		3
92	Guidelines of care for cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>1996</b> , 34, 830-836	4-5	46
91	The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?. <b>1996</b> , 5, 6-10		47

90	Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. <b>1996</b> , 5, 31-36	96
89	The efficacy of antimalarials in systemic lupus erythematosus. <b>1996</b> , 5, 23-27	15
88	The use of antimalarials in combination with other disease modifying agents in RA [The British experience. <b>1996</b> , 5, 50-58	6
87	The history of antimalarials. <b>1996</b> , 5, 2-3	52
86	Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. <b>1996</b> , 5, 4-10	55
85	Differential uptake of chloroquine by human keratinocytes and melanocytes in culture. <b>1996</b> , 288, 211-5	9
84	Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. <b>1996</b> , 5, 237-41	98
83	Phototesting and photoprotection in LE. <b>1997</b> , 6, 167-74	56
82	Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. <b>1997</b> , 19, 913-23	81
81	Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. <b>1997</b> , 40, 927-35	46
80	Management of collagen vascular diseases in childhood. <b>1998</b> , 16, 579-92	14
79	Hydroxychloroquine: past, present, future. <b>1998</b> , 7, 65-7	30
78	A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. <b>1998</b> , 7, 80-5	202
77	Chloroquine inhibits proinflammatory cytokine release into human whole blood. <b>1998</b> , 274, R1058-64	58
76	Photosensitivity in collagen vascular diseases. <b>1999</b> , 18, 293-6	13
75	Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 42, 983-987	4-5 145
74	Antimalarials. <b>2001</b> , 19, 147-60, ix	55
73	Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. <b>2001</b> , 2, 253-62	188

72	Antimalarials. <b>2001</b> , 14, 143-153		1
71	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <b>2002</b> , 46, 1460-9		169
70	LUPUS ERYTHEMATOSUS AND THE SKIN. <b>2004</b> , 855-876		1
69	Factors associated with chloroquine-induced retinopathy in rheumatic diseases. <b>2004</b> , 13, 119-24		28
68	[Synthetic antimalarials]. <b>2005</b> , 132, 665-74		5
67	Optimal use of antimalarials in treating cutaneous lupus erythematosus. <b>2005</b> , 6, 1-11		29
66	Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?. <b>2007</b> , 26, 1248-53		25
65	Stopping the rot: the stories behind methotrexate, sulphasalazine and hydroxychloroquine. <b>2008</b> , 11, 61-65		2
64	[Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up]. <b>2009</b> , 226, 891-6		3
63	[Antimalarials. A treatment option for every lupus patient!?.]. <b>2009</b> , 68, 584, 586-90		4
62	Treatment of cutaneous lupus erythematosus. <b>2010</b> , 19, 1125-36		33
61	The role of antimalarial agents in the treatment of SLE and lupus nephritis. <i>Nature Reviews Nephrology</i> , <b>2011</b> , 7, 718-29	14.9	166
60	Cutaneous lupus erythematosus: update of therapeutic options part I. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, e179-93	4.5	120
59	Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 717-721.e2	4.5	51
58	PHARMACOLOGY AND DRUG THERAPY. <b>2011</b> , 71-126		18
57	Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus". <i>Archives of Dermatology</i> , <b>2011</b> , 147, 1267-8		2
56	Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. <i>Archives of Dermatology</i> , <b>2011</b> , 147, 1261-7		94
55	Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. <i>Clinical and Experimental Dermatology</i> , <b>2012</b> , 37, 327-34	1.8	32

54	Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). <i>Modern Rheumatology</i> , <b>2013</b> , 23, 318-322	3.3	22
53	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 43, 264-72	5.3	88
52	A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. <i>Internal Medicine Journal</i> , <b>2013</b> , 43, 547-53	1.6	15
51	Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. <i>Anais Brasileiros De Dermatologia</i> , <b>2014</b> , 89, 118-25	1.6	10
50	Massive and painful ascites as a presenting manifestation of systemic lupus erythematosus flare: a case report and literature review. <i>Revista Medica De Chile</i> , <b>2014</b> , 142, 255-60	0.5	4
49	Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> ,		25
48	Pharmacology of Chloroquine and Hydroxychloroquine. <b>2014</b> , 35-63		65
47	Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. <i>JAMA Ophthalmology</i> , <b>2014</b> , 132, 1199-208	3.9	38
46	Cutaneous deposits. <i>American Journal of Dermatopathology</i> , <b>2014</b> , 36, 1-48	0.9	26
45	Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. <i>Psychosomatics</i> , <b>2014</b> , 55, 409-413	2.6	15
44	15-hydroxyprostaglandin dehydrogenase is upregulated by hydroxychloroquine in rheumatoid arthritis fibroblast-like synoviocytes. <i>Molecular Medicine Reports</i> , <b>2015</b> , 12, 4141-4148	2.9	7
43	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. <i>Inflammopharmacology</i> , <b>2015</b> , 23, 231-69	5.1	300
42	Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. <i>Pediatric Pulmonology</i> , <b>2015</b> , 50, 410-9	3.5	30
41	Pharmacology and Drug Therapy: Nonbiologic Therapies. <b>2016</b> , 140-160.e16		
40	CHOROIDAL THICKNESS IN MULTISYSTEMIC AUTOIMMUNE DISEASES WITHOUT OPHTHALMOLOGIC MANIFESTATIONS. <i>Retina</i> , <b>2017</b> , 37, 529-535	3.6	24
39	Reply to Escobedo et al. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 1181-1182	7	1
38	Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. <i>Ecancermedicalscience</i> , <b>2017</b> , 11, 781	2.7	133
37	Mirtazapine-induced hyperpigmentation with type II histopathologic findings. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 1077-1079	1.4	0



36	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 709-722	4.5	12
35	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 35, 101735	8.4	71
34	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus - Part 2: Therapy, risk factors and other special topics. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1371-1395	1.2	1
33	S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematosus - Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1371-1395	1.2	0
32	Hydroxychloroquine. <b>1990</b> , 235-247		1
31	Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause. <b>2014</b> , 65-83		3
30	4-Aminoquinolines. <i>Handbook of Experimental Pharmacology</i> , <b>1984</b> , 3-60	3.2	14
29	Lupus Erythematosus. <b>2015</b> , 547-560		1
28	Differential uptake of chloroquine by human keratinocytes and melanocytes in culture. <b>1996</b> , 288, 211		1
27	Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). <i>Modern Rheumatology</i> , <b>2013</b> , 23, 318-22	3.3	8
26	PHARMACOLOGY AND DRUG THERAPY. <b>2005</b> , 76-141		9
25	Connective Tissue Diseases. <i>Clinics in Plastic Surgery</i> , <b>1993</b> , 20, 77-90	3	3
24	Antimalarial Therapy in SLE. <i>Clinics in Rheumatic Diseases</i> , <b>1982</b> , 8, 279-298		25
23	The Treatment of SLE: The Case for Conservative Management. <i>Clinics in Rheumatic Diseases</i> , <b>1982</b> , 8, 299-313		10
22	Chloroquine and Hydroxychloroquine in Rheumatological Therapy. <i>Clinics in Rheumatic Diseases</i> , <b>1980</b> , 6, 545-566		67
21	ANTIMALARIAL AGENTS AND LUPUS. <i>Rheumatic Disease Clinics of North America</i> , <b>1994</b> , 20, 243-263	2.4	96
20	Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239675	3.7	4
19	Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. <i>Drug Safety</i> , <b>2001</b> , 24, 1055-63	5.1	34

18	SYSTEMIC LUPUS ERYTHEMATOSUS. <b>2009</b> , 1047-1062		
17	Ancillary Testing in Screening for Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 155-226		
16	Screening for Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 227-245		
15	Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 133-154		
14	Definitions of Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 85-94		
13	Natural History of Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 107-131		
12	Antiinflammatory and Immunosuppressive Drugs in the Treatment of Systemic Lupus Erythematosus. <b>1986</b> , 328-351		
11	Systemic Treatment of Dermatoses. <b>1991</b> , 1170-1182		
10	Allergien, Immunmangel- und Autoaggressionskrankheiten. <b>1991</b> , 303-330		
9	Allergien, Immunmangel- und Autoaggressionskrankheiten. <b>1994</b> , 349-379		
8	TREATMENT OF REFRACTORY CUTANEOUS LUPUS ERYTHEMATOSUS. <i>Rheumatic Disease Clinics of North America</i> , <b>1995</b> , 21, 99-115	2.4	17
7	Antimalarials and Other Second-Line Drugs. <i>Treatment in Clinical Medicine</i> , <b>1983</b> , 159-164		0
6	Treatment: Disease-Modifying Therapies. <i>Rheumatic Disease Clinics of North America</i> , <b>1988</b> , 14, 223-243	2.4	9
5	The Treatment of Systemic Lupus Erythematosus: The Case for Conservative Management. <i>Clinics in Rheumatic Diseases</i> , <b>1979</b> , 5, 641-655		1
4	Cutaneous Reactions to Rheumatological Drugs. <i>Clinics in Rheumatic Diseases</i> , <b>1982</b> , 8, 493-516		25
3	Lysosomotropic agents in AIDS treatment. <i>Western Journal of Medicine</i> , <b>1987</b> , 146, 234		1
2	Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2013</b> , 6, 27-38	1.2	13
1	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X211073001	3.8	5

